Andrew Cheng
Chief Executive Officer chez AKERO THERAPEUTICS, INC.
Fortune : 16 M $ au 31/03/2024
Profil
Andrew Cheng is currently the President, Chief Executive Officer & Director at Akero Therapeutics, Inc., a Non-Executive Director at MorphoSys AG, an Independent Director at Vera Therapeutics, Inc., and a Director at Boys & Girls Clubs of Metro Los Angeles.
He previously served as an Independent Director at Arbutus Biopharma Corp.
from 2019 to 2022, and held positions as a Director at Syntimmune, Inc., a Director at Global Virus Network, and the Chief Medical Officer & Executive Vice President at Gilead Sciences, Inc. from 1999 to 2018.
Dr. Cheng received his undergraduate degree from The Johns Hopkins University in 1988 and his doctorate from Columbia University College of Physicians & Surgeons in 1996.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AKERO THERAPEUTICS, INC.
0,85% | 13/03/2024 | 589 447 ( 0,85% ) | 15 M $ | 31/03/2024 |
| 18/03/2024 | 17 488 ( 0,03% ) | 754 083 $ | 31/03/2024 |
Postes actifs de Andrew Cheng
| Sociétés | Poste | Début |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Chief Executive Officer | 01/09/2018 |
| VERA THERAPEUTICS, INC. | Director/Board Member | 01/05/2017 |
| MORPHOSYS AG | Director/Board Member | 18/05/2022 |
Boys & Girls Clubs of Metro Los Angeles
 Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Boys & Girls Clubs of Metro Los Angeles is a non-profit organization that was founded in December 2015 to provide a sustainable solution to the opportunity crises facing vulnerable children in the neediest neighborhoods of Los Angeles. Boys & Girls Clubs of Metro Los Angeles is based in Los Angeles, CA, and has subsidiaries in the United States. The organization operates four clubs in Bell Gardens, Challengers, Downs, and Willowbrook, and offers nationally recognized, research-based programs and activities in three core areas: academic success, good character and citizenship, and healthy lifestyles. The organization empowers youth to explore a future with endless possibilities by offering creative programming, such as new approaches to science, technology, engineering, and math (STEM) created in collaboration with community partners. The non-profit company was founded in 2015, and the CEO is Patrick Mahoney. | Director/Board Member | - |
Anciens postes connus de Andrew Cheng
| Sociétés | Poste | Fin |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 25/05/2022 |
| GILEAD SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 07/09/2018 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Director/Board Member | - |
Global Virus Network
 Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Director/Board Member | - |
Formation de Andrew Cheng
| The Johns Hopkins University | Undergraduate Degree |
| Columbia University College of Physicians & Surgeons | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| MORPHOSYS AG | Health Technology |
| AKERO THERAPEUTICS, INC. | Health Technology |
| VERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Commercial Services |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Boys & Girls Clubs of Metro Los Angeles is a non-profit organization that was founded in December 2015 to provide a sustainable solution to the opportunity crises facing vulnerable children in the neediest neighborhoods of Los Angeles. Boys & Girls Clubs of Metro Los Angeles is based in Los Angeles, CA, and has subsidiaries in the United States. The organization operates four clubs in Bell Gardens, Challengers, Downs, and Willowbrook, and offers nationally recognized, research-based programs and activities in three core areas: academic success, good character and citizenship, and healthy lifestyles. The organization empowers youth to explore a future with endless possibilities by offering creative programming, such as new approaches to science, technology, engineering, and math (STEM) created in collaboration with community partners. The non-profit company was founded in 2015, and the CEO is Patrick Mahoney. | Commercial Services |
